ESTRO 2024 - Abstract Book

S1430

Clinical - Head & neck

ESTRO 2024

Keywords: Recurrence, GTV, CTV

References:

Gregoire V et al. Delineation of primary tumor clinical target volumes (CTV-P) in laryngeal, hypoharyngeal, oropharyngeal and oral cavity squamous cell carcinoma: AIRO, CACA, DAHANCA, EORTC, GEORCC, GORTEC, HKNPCSG, HNCIG, IAG-KHT, LPRHHT, NCIC, NRG oncology, PHNS, SBRT, SOMERA, SRO, SSHNO, TROG consensus guidelines. Radiotherapy Oncology 126 (2018) 3-24

2803

Digital Poster

Treatment outcomes of intra-arterial chemoradiotherapy for oral cavity squamous cell carcinoma.

Yutaka Toyomasu, Akinori Takada, Takamitsu Mase, Kazuki Omori, Akito Taniguchi, Tomoko Kawamura, Hajime Sakuma, Yoshihito Nomoto

Mie University Hospital, Radiology, Mie, Japan

Purpose/Objective:

This retrospective study aimed to evaluate the treatment outcomes in patients with oral cavity squamous cell carcinoma (OCSCC) treated with intra-arterial chemoradiotherapy (IA-CRT) at a single institution.

Material/Methods:

Between June 2013 and September 2021, 38 patients with OCSCC underwent IA-CRT. Seventeen patients received induction chemotherapy (either cisplatin and fluorouracil or cisplatin, fluorouracil and docetaxel). Intra-arterial chemotherapy regimen consisted of weekly cisplatin (35-50 mg/m2) for 6 to 8 cycles. Patients were received curative radiotherapy (70 Gy in 35 fractions). Overall survival (OS), progression-free survival (PFS), local control (LC), and distant metastasis-free survival (DMFS) were calculated using the Kaplan-Meier method. The log-rank test and the Cox proportional hazards model were used for univariate and multivariate analyses, respectively.

Results:

Most patients presented with stage Ⅳ (n = 31, 82%). The median follow-up time was 35 months (range, 6-88 months). The 3-year OS, PFS, LC, and DMFS rates were 68%, 57%, 84%, and 64%, respectively. Fourteen (37%) of 38 patients were died. Disease recurrence occurred in 14 patients (n=14, 37%): local recurrence in 5 patients (13%), regional recurrence in 8 patients (21%), and distant metastasis in 7 patients (18%). Grade 3 or greater late adverse events occurred in one patient (3%): osteonecrosis of the jaw (grade 3). In univariate analysis, N stage was the significant prognostic factor for OS (p = 0.039), and induction chemotherapy was for OS (p = 0.031) and DMFS (p =